Integration agreement secured with Beth Israel Deaconess Medical Center, Boston USA
▪ Integration follows successful trial of EchoSolv-AS by Beth Israel researchers on a historical cohort of 31,000 patients
▪ Trial...
Integration agreement secured with Beth Israel Deaconess Medical Center, Boston USA
▪ Integration follows successful trial of EchoSolv-AS by Beth Israel researchers on a historical cohort of 31,000 patients
▪ Trial...
“With the 200 cm length, the R2P NaviCross catheter provides physicians performing percutaneous transluminal endovascular procedures from the radial artery a valuable tool to enhance their ability to safely and efficiently complete more...
“With the 200 cm length, the R2P NaviCross catheter provides physicians performing percutaneous transluminal endovascular procedures from the radial artery a valuable tool to enhance their ability to safely and efficiently complete more...
Hechingen, November 26th, 2024 -- Shortly after receiving the CE certification for its BeFlared Stent Graft System, the world’s first dedicated bridging stent for fenestrated endovascular aneurysm repair (FEVAR), Bentley announced the...
Hechingen, November 26th, 2024 -- Shortly after receiving the CE certification for its BeFlared Stent Graft System, the world’s first dedicated bridging stent for fenestrated endovascular aneurysm repair (FEVAR), Bentley announced the...
Embolic device designed for improved preparation, delivery, and deep vessel filling for treating tumors and other interventional oncology uses.
Salt Lake City (UT) – Fluidx Medical Technology, Inc. announced today that the first...
Embolic device designed for improved preparation, delivery, and deep vessel filling for treating tumors and other interventional oncology uses.
Salt Lake City (UT) – Fluidx Medical Technology, Inc. announced today that the first...
NEW IBERIA, LA – Cardiovascular Institute of the South (CIS) and Iberia Medical Center (IMC) are the first in Acadiana to use the new FDA-approved Esprit™ BTK (Below the Knee) Everolimus Eluting Resorbable Scaffold System, a first-of-its-kind...
NEW IBERIA, LA – Cardiovascular Institute of the South (CIS) and Iberia Medical Center (IMC) are the first in Acadiana to use the new FDA-approved Esprit™ BTK (Below the Knee) Everolimus Eluting Resorbable Scaffold System, a first-of-its-kind...
Hechingen, November 20th, 2024. With two certificates granted by TÜV, Bentley achieved another break-through in extending indications for its stents in complex aortic interventions. Thanks to one certificate, the Bentley BeGraft stent now is...
Hechingen, November 20th, 2024. With two certificates granted by TÜV, Bentley achieved another break-through in extending indications for its stents in complex aortic interventions. Thanks to one certificate, the Bentley BeGraft stent now is...
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...